# TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma

> **NCT01605734** · PHASE2 · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 120 (estimated)

## Conditions studied

- PHENYTOIN/SORAFENIB [VA Drug Interaction]
- Carcinoma, Hepatocellular

## Interventions

- **PROCEDURE:** TACE
- **DRUG:** sorafenib combined with TACE

## Key facts

- **NCT ID:** NCT01605734
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-07
- **Primary completion:** 2013-12
- **Final completion:** 2015-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2012-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01605734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01605734, "TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01605734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*